<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987948</url>
  </required_header>
  <id_info>
    <org_study_id>H005</org_study_id>
    <nct_id>NCT00987948</nct_id>
  </id_info>
  <brief_title>Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels</brief_title>
  <official_title>Pilot Study of the Effect of Maraviroc Intensification on Peripheral Blood Monocyte HIV DNA Levels When Given to HIV-Infected Subjects Stable on Highly Active Antiretroviral Therapy With Undetectable Plasma HIV RNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the
      bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is
      a HIV medication that works by blocking the entry of HIV in cells including
      monocytes/macrophages that use a receptor called CCR5. The study hypothesis is that the
      addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high
      levels of HIV-infected monocyte/macrophages will lead to a decrease in the levels of infected
      monocyte/macrophages and to decrease in brain inflammation as studied by magnetic resonance
      spectroscopy (MRS, a form of MRI study).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Week 24 minus baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Weeks in Neuropsychological Performance As Measured by Age- and Education-Adjusted Z-Scores</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>The Z-score represents the number of standard deviations away from the mean, with positive Z-scores representing better neuropsychological performance and negative Z-scores representing poorer neuropsychological performance. Z-scores have been adjusted based on age- and education-matched norms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc (Selzentry)</intervention_name>
    <description>dosage varies with other medications being taken; will follow package insert guidelines</description>
    <arm_group_label>Maraviroc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection as documented by ELISA and confirmed by either Western blot, HIV-1
             culture, HIV-1 antigen, plasma HIV-1 RNA by RT-PCR or bDNA at any time prior to study
             entry.

          -  Receipt of ARV medication uninterrupted for &gt; 1 year leading up to the screening
             period with demonstrated HIV RNA &lt; 50 copies/ml for a period of 1 year.&quot;

          -  Willingness for both males and females of childbearing potential to utilize 2
             effective contraception methods (2 separate forms, one of which must be an effective
             barrier method), be non-heterosexually active or have a an exclusive vasectomized
             partner from screening throughout the duration of the study treatment and for 30 days
             following the last dose of study drugs.

          -  Age &gt;18 years.

          -  Ability and willingness to provide written informed consent

          -  The following laboratory parameters documented within 30 days prior to study entry:

               -  Hemoglobin &gt;8.0

               -  Absolute neutrophil count &gt;500

               -  Platelet count &gt;40,000

               -  AST (SGOT) and ALT (SGPT) &lt;5 x ULN

               -  Creatinine &lt;1.5 x ULN

               -  Lipase &lt;2.0 x ULN

               -  Estimated creatinine clearance &gt; 60 mL/min.

          -  HIV DNA within peripheral blood mononuclear cells &gt; 100 copies/mL

          -  Not currently receiving Maraviroc as part of ARV regimen

        Exclusion Criteria:

          -  Past or present HIV opportunistic infection of the brain, learning disability, head
             injury with prolonged loss of consciousness or cognitive sequelae, or other non-HIV
             risk factor that may impact cognitive performance.

          -  Any factor that precludes MRI scan including presence of metal or exposure to metal
             work (e.g., metal grinder/worker) and claustrophobia

          -  History of seizure disorder

          -  History of myocardial infarction, angina, congestive heart failure, peripheral
             vascular disease, angioplasty or cardiac surgery

          -  Current malignancy or history of past malignancies excluding basal cell CA

          -  Any immunomodulator, HIV vaccine, or investigational therapy within 30 days of study
             entry.

          -  Any vaccination within 30 days of study entry.

          -  Requirement for acute therapy for other AIDS-defining illness or other serious medical
             illnesses (in the opinion of the site investigator) within 14 days prior to study
             entry.

          -  Other chronic illnesses including diabetes, autoimmune diseases, and endocrinopathies,
             except subjects on stable physiologic replacement therapy for low testosterone or
             thyroid levels

          -  Known hypersensitivity to Maraviroc

          -  Any condition which, in the opinion of the investigator, would compromise the
             subject's ability to participate in the study

          -  Current active substance or alcohol dependence

          -  Pregnancy or breast-feeding, intent to become pregnant during the course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecilia M Shikuma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hawaii at Manoa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hawaii Center for AIDS</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <results_first_submitted>January 20, 2015</results_first_submitted>
  <results_first_submitted_qc>February 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2017</results_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>dementia</keyword>
  <keyword>High HIV DNA within CD14+ PBMCs</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Maraviroc</title>
          <description>maraviroc (Selzentry): dosage varies with other medications being taken; will follow package insert guidelines</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maraviroc</title>
          <description>maraviroc (Selzentry): dosage varies with other medications being taken; will follow package insert guidelines</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells</title>
        <description>Week 24 minus baseline</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <population>Outcome measure in the 12 patients who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc</title>
            <description>maraviroc (Selzentry): dosage varies with other medications being taken; will follow package insert guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells</title>
          <description>Week 24 minus baseline</description>
          <population>Outcome measure in the 12 patients who completed the study.</population>
          <units>Log-10 copies/10^6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.00" upper_limit="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Weeks in Neuropsychological Performance As Measured by Age- and Education-Adjusted Z-Scores</title>
        <description>The Z-score represents the number of standard deviations away from the mean, with positive Z-scores representing better neuropsychological performance and negative Z-scores representing poorer neuropsychological performance. Z-scores have been adjusted based on age- and education-matched norms.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <population>6 of 12 patients who completed the study who had mild to moderate cognitive impairment</population>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc</title>
            <description>maraviroc (Selzentry): dosage varies with other medications being taken; will follow package insert guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Weeks in Neuropsychological Performance As Measured by Age- and Education-Adjusted Z-Scores</title>
          <description>The Z-score represents the number of standard deviations away from the mean, with positive Z-scores representing better neuropsychological performance and negative Z-scores representing poorer neuropsychological performance. Z-scores have been adjusted based on age- and education-matched norms.</description>
          <population>6 of 12 patients who completed the study who had mild to moderate cognitive impairment</population>
          <units>Z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.35" upper_limit="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc</title>
          <description>maraviroc (Selzentry): dosage varies with other medications being taken; will follow package insert guidelines</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Patient developed abdominal pain at 4 weeks post initiation of study; diagnosed to have pancreatitis. Study medications stopped with resolution of symptoms. SAE assessed as possibly related to maraviroc. MedWatch form filled out.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cecilia M Shikuma</name_or_title>
      <organization>Hawaii Center for AIDS, University of Hawaii</organization>
      <phone>8086921328</phone>
      <email>shikuma@hawaii.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

